Patents Assigned to Heska Corporation
  • Patent number: 7556963
    Abstract: The present invention relates to canine and feline proteins. In particular, the present invention discloses feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain proteins. The present invention also includes feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain nucleic acid molecules encoding such proteins, antibodies raised against such proteins and/or inhibitors of such proteins or nucleic acid molecules. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and/or inhibitors, as well as their use to evaluate and regulate an immune response in an animal.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: July 7, 2009
    Assignee: Heska Corporation
    Inventor: Ramani S. Wonderling
  • Patent number: 7482128
    Abstract: The present invention provides isolated monoclonal antibodies that selectively bind albumin from animals. Also provided are methods using such antibodies for the detection of early renal disease in animals. The method includes the steps of (a) obtaining a sample from an animal to be tested; (b) contacting the sample with an antibody having a greater avidity for feline albumin than for other proteins or components in the sample; (c) detecting the complex formed by the antibody and albumin; and (d) determining the amount of albumin in the sample from the amount of antibody-albumin complex detected. An amount of albumin in the range of from 10 ?g/ml to about 300 ?g/ml indicates the presence of early renal disease.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: January 27, 2009
    Assignee: Heska Corporation
    Inventors: Wayne A. Jensen, Shirley Wu Hunter, Karen Sverlow, Janet S. Andrews
  • Patent number: 7476524
    Abstract: The present invention relates to canine COX-1 and COX-2 proteins; to canine COX-1 and COX-2 nucleic acid molecules, including those that encode such COX-1 and COX-2 proteins, respectively; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit COX-2 activity, as well as the use of such therapeutic compositions to treat animals.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: January 13, 2009
    Assignee: Heska Corporation
    Inventors: Nancy Wisnewski, Kevin S. Brandt
  • Patent number: 7476728
    Abstract: The present invention relates to flea GABA receptor subunit nucleic acid molecules; to flea GABA receptor subunit proteins encoded by such nucleic acid molecules; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and inhibitory compounds, particularly those that specifically inhibit flea GABA receptor subunit activity, as well as the use of such therapeutic compositions to treat animals.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: January 13, 2009
    Assignee: Heska Corporation
    Inventors: Nancy Wisnewski, Kevin S. Brandt
  • Patent number: 7427661
    Abstract: The present invention relates to canine interleukin-5 proteins; canine interleukin-5 nucleic acid molecules, including those that encode canine interleukin-5 proteins; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: September 23, 2008
    Assignee: Heska Corporation
    Inventors: Shumin Yang, Catherine A. McCall, Eric R. Weber
  • Patent number: 7419793
    Abstract: The present invention relates to tick octopamine receptor nucleic acid molecules; to tick octopamine receptor proteins encoded by such nucleic acid molecules; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes inhibitory compounds, particularly those that specifically inhibit tick octopamine receptor activity, as well as the use of such compounds to treat animals.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: September 2, 2008
    Assignee: Heska Corporation
    Inventor: Kevin S. Brandt
  • Patent number: 7396909
    Abstract: The present invention relates to immunogenic Toxoplasma gondii proteins, to T. gondii nucleic acid molecules, including those that encode such proteins and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules and antibodies. Also included in the present invention are compositions comprising such proteins, nucleic acid molecules and/or antibodies, as well as the use of such compositions to inhibit oocyst shedding by cats due to infection with T. gondii. The present invention also includes the use of certain T. gondii-based antisera to identify such nucleic acid molecules and proteins, as well as nucleic acid molecules and proteins identified by such methods. The present invention also relates to novel methods for the detection of cysts and oocysts.
    Type: Grant
    Filed: December 29, 2005
    Date of Patent: July 8, 2008
    Assignee: Heska Corporation
    Inventor: Michael James Milhausen
  • Patent number: 7396536
    Abstract: The present invention relates to: parasitic helminth cuticlin proteins; parasitic helminth cuticlin nucleic acid molecules, including those that encode such cuticlin proteins; antibodies raised against such cuticlin proteins; and compounds that inhibit parasitic helminth cuticlin activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: July 8, 2008
    Assignee: Heska Corporation
    Inventors: Ramaswamy Chandrashekar, Tony H. Morales
  • Patent number: 7385045
    Abstract: The present invention relates to B7 proteins; to B7 nucleic acid molecules, including those that encode such B7 proteins; to antibodies raised against such B7 proteins; and to therapeutic compounds that regulate B7 function. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: June 10, 2008
    Assignee: Heska Corporation
    Inventors: Shumin Yang, Gek-Kee Sim
  • Patent number: 7378275
    Abstract: The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present invention discloses nucleic acid molecules encoding canine IgG, including species-specific regions of the heavy chain of canine IgG, and canine IL-13R alpha chain (IL-13R?) proteins, particularly canine interleuken receptor alpha 1 (IL-13R?1) and canine interleuken receptor alpha 2 (IL-13R?2) proteins. Also included are canine IgG and IL-13R? proteins, antibodies having selectivity for such proteins, inhibitors of such proteins and/or nucleic acid molecules, cells transformed with said nucleic acid molecules, assays employing such cells, nucleic acids molecules, proteins, antibodies and/or inhibitors, and therapeutic compositions comprising said nucleic acids molecules, proteins, antibodies and/or inhibitors.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: May 27, 2008
    Assignee: Heska Corporation
    Inventors: Catherine A. McCall, Liang Tang
  • Patent number: 7348410
    Abstract: The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: March 25, 2008
    Assignee: Heska Corporation
    Inventors: Patrick J. Gaines, Nancy Wisnewski
  • Publication number: 20080045693
    Abstract: The present invention is directed to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal. The present invention also relates to ectoparasite saliva proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to obtain such proteins and to use such proteins to identify animals susceptible to or having allergic dermatitis. The present invention also includes therapeutic compositions comprising such proteins and their use to treat animals susceptible to or having allergic dermatitis.
    Type: Application
    Filed: March 30, 2007
    Publication date: February 21, 2008
    Applicant: HESKA CORPORATION
    Inventors: Shirley Hunter, Gek-Kee Sim, Eric Weber
  • Patent number: 7314627
    Abstract: The present invention relates to a method to introduce a nucleic acid molecule into a felid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic lipid complex to elicit and/or enhance an immune response. In one embodiment, this method enhances the immune response in a felid compared to a method in which a naked DNA vaccine is administered to a felid. Also provided is a method to deliver a nucleic acid to a felid. This method comprises parenterally administering to the felid a composition that includes a nucleic acid molecule complexed with a cationic lipid.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: January 1, 2008
    Assignee: Heska Corporation
    Inventors: Joel R. Haynes, Ramani S. Wonderling, Dan T. Stinchcomb
  • Publication number: 20070202132
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Application
    Filed: December 12, 2006
    Publication date: August 30, 2007
    Applicant: HESKA CORPORATION
    Inventors: Jay Morgenstern, Christine Bizinkauskas, Andrzej Konieczny, Andrew Brauer
  • Patent number: 7256263
    Abstract: The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: August 14, 2007
    Assignee: Heska Corporation
    Inventors: Catherine A. McCall, Shirley Wu Hunter, Eric R. Weber
  • Patent number: 7247447
    Abstract: The present invention relates to flea peritrophin proteins; to flea peritrophin nucleic acid molecules, including those that encode such flea peritrophin proteins; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain and use such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit flea peritrophin activity, as well as the use of such therapeutic compositions to treat animals.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: July 24, 2007
    Assignee: Heska Corporation
    Inventors: Patrick J. Gaines, Nancy Wisnewski
  • Publication number: 20070154920
    Abstract: The present invention is directed to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal. The present invention includes a saliva protein collection apparatus capable of collecting ectoparasite saliva proteins substantially free of contaminating material. The present invention also relates to ectoparasite saliva proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to obtain such proteins and to use such proteins to identify animals susceptible to or having allergic dermatitis. The present invention also includes therapeutic compositions comprising such proteins and their use to treat animals susceptible to or having allergic dermatitis.
    Type: Application
    Filed: December 14, 2006
    Publication date: July 5, 2007
    Applicant: HESKA CORPORATION
    Inventors: Glenn Frank, Shirley Hunter, Lynda Wallenfels
  • Patent number: 7226996
    Abstract: The present invention relates to equine Fc epsilon receptor alpha chain nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes methods to detect IgE using such proteins and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to mediate Fc epsilon receptor-mediated biological responses.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: June 5, 2007
    Assignee: Heska Corporation
    Inventors: Eric R. Weber, Catherine A. McCall
  • Patent number: 7223578
    Abstract: The present invention relates to canine COX-1 and COX-2 proteins; to canine COX-1 and COX-2 nucleic acid molecules, including those that encode such COX-1 and COX-2 proteins, respectively; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit COX-2 activity, as well as the use of such therapeutic compositions to treat animals.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: May 29, 2007
    Assignee: Heska Corporation
    Inventors: Nancy Wisnewski, Kevin S. Brandt
  • Patent number: RE40374
    Abstract: The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF nucleic acid molecules, including those that encode canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins, respectively; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: June 10, 2008
    Assignee: Heska Corporation
    Inventor: Shumin Yang